Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

On the 10/20 conference call Dr. JL said specifica

Message Board Public Reply | Private Reply | Keep | Replies (1)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 153798
(Total Views: 632)
Posted On: 01/19/2021 1:56:46 PM
Posted By: thriftycents
Re: havasu78 #73307
On the 10/20 conference call Dr. JL said specifically that he was never thrilled with the 2 dose regiment for severe to critical. He thought all along that it should be 3 to 4 doses. The FDA said no and that we should go with 2 doses in each trial. In the spring he also said that he asked if we could administer the first dose via IV for the sickest of patients to get 100% occupancy sooner but again was denied by the FDA. If you recall, he also asked for 700mg to be the dose for cancer patients...again denied by the FDA and we are required to try 525mg before 700mg (even with the data from right to try patients who responded much better to 700mg).

From these examples I believe much of the blame should be put on the FDA. I am not sure why they aren't amenable to the dosing regiments requested but the company and their consultants (including Dr. Patterson) have clearly tried multiple times to get what they believe to be better dosing regiments approved.

My understanding is that there is a bit of a dance played between the sponsor and the FDA when it comes to trial design. We cannot look at a trial and say that everything that it contains was at the request of the company. There is certainly a give and take. While we can suggest things we would like at the end of the day we are at the mercy of the FDA and going against their recommendations is a very expensive gamble.


(12)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us